Antibody Drug Conjugates Seminar
Date: August 29, 2020 @ 1:25 pm – @ 5:15 pm
Location: Online Webinar through Zoom Conference
With the accelerated approval to Trodelvy in 2020, 9 antibody-drug conjugates (ADCs) now on the market have truly proven their potential. The Chinese American Biopharmaceutical Society (CABS) will host an ADC seminar on Aug 29, 2020 at 1:25-4:30pm. Brought together ADC experts from Seattle Genetics, Sutro Biopharma, Genentech, and Eli Lilly, the seminar will delve into the pioneering development of ADC from early discovery through to manufacturing CMC and clinical study. Join us to get exposed to ground-breaking ADC science and case studies and to network with ADC industrial professionals.
Date: August 29th 2020, Saturday, 1:25-4:30 PM PST
Registration not required. Please click the link below to join the webinar:
Agenda:
1:25 to 1:30 PM Welcome Remarks from CABS. Yang Tian, PhD, President, CABS.
1:30 to 2:15 PM Antibody Drug Conjugates - Using a Novel Technology to Produce First in Class Immune Modulating Cancer Drugs. Kristin Bedard, PhD, VP of Immuno-Biology, Sutro Biopharma, South San Francisco.
2:15 to 3:00 PM Clinical Pharmacology Strategies in Supporting Drug Development and Approval of Antibody Drug Conjugates. Chunze Li, PhD, Director/Principal Scientist/Group Leader, Oncology Clinical Pharmacology, Genentech, South San Francisco.
3:00 to 3:45 PM CMC Challenges and Opportunities in ADC Drug Development and Lifecycle Management. Tao Li, Senior Manager, Regulatory Affairs CMC, Seattle Genetics, Seattle.
3:45 to 4:30 PM Expanding the Application of Antibody Drug Conjugates through Chemistry. Thomas Pillow, PhD, Senior Scientist, Discovery Chemistry Department, Genentech, South San Francisco.
4:30 to 5:15 PM Antibody Drug Conjugate (ADC) Beyond Oncotherapies. Songqing Na, PhD, Research Fellow, Immunology Research, Lilly Biotechnology Center, Eli Lilly and Company, San Diego.
Speakers Background:
Dr. Kristin Bedard is the Vice President of Immuno-biology at Sutro Biopharma where her team is responsible for the preclinical development of immuno-oncology assets. She has over twenty years of experience in innate immunity, cancer research and drug development and was most recently the scientific co-founder and Chief Scientific Officer of Immuno-oncology at Kineta, Inc. where she led early discovery and development programs in infectious disease and oncology. Her team progressed the antiviral candidate, LHF-535, from discovery into clinical development for the treatment of Arenavirus infection. Additionally, she developed a proprietary innate immune screening platform and identified novel small molecule RIG-I agonists for the treatment of solid tumors which were licensed to Pfizer in 2017. Her work in innate immunity has been well published and she is the co-inventor on more than ten patents for novel immuno-oncology compounds and methods of identification. Prior to Kineta, Dr. Bedard was a senior fellow at the Fred Hutchinson Cancer Research Center where her research focused on viral induced skin and cervical cancers. She completed her PhD in molecular virology at the University of California, Irvine. Dr. Bedard volunteers her time as a board member for the Healthcare Businesswomen’s Association where she received the Everest Award in 2019 for her dedication and leadership. She also serves as chairwoman and scientific reviewer for the National Institutes of Health small business grant division.
Dr. Chunze Li is currently a Director/Principal Scientist/Group Leader in Oncology Clinical Pharmacology at Genentech. She oversees strategic clinical pharmacology support for diverse oncology molecules, including antibody-drug conjugates, Immune-cell bispecifics, cell therapy, hematological drugs, HER2 targeted therapies, and SC development for monoclonal antibodies. She is passionate about strategic implementation of quantitative clinical pharmacology to optimize the oncology drug development. Prior to Genentech, Dr. Li worked as Associate Director at Pfizer and as Research Fellow at Merck to provide Clin Pharm and DMPK support in drug discovery and development of small molecules, therapeutic proteins and monoclonal antibodies across multiple diseases. Dr. Li obtained her PhD degree in Pharmaceutical Chemistry at UCSF with Dr. Leslie Z. Benet. She has published over 50 peer-reviewed papers and book chapters in the field of clinical pharmacology, drug metabolism and pharmacokinetics.
Tao Li has more than 19 years of pharmaceutical industry experience in Regulatory Affairs CMC, drug discovery and development. Prior to Seattle Genetics, Tao worked at Abbott/AbbVie as a senior scientist focused on discovery and developing clinical candidates including new ADC payloads; most recently in RA CMC, with primary responsibility for post-approval lifecycle management of multiple marketed products including small molecule tablets, parenteral, and biologics. During his 1.5 years with Seattle Genetics, he played a key role in the Module 3 preparation, submissions and approvals for Tukysa™ NDA/MAAs. He is also responsible for multiple early stage programs as the RA CMC leader and has advanced three new biologics and antibody-drug conjugate (ADC) INDs/IMPDs into clinical trials. Tao holds a BSc in Chemistry and a MSc in Medicinal Chemistry from Shandong University. In addition, he has a graduate certificate of Regulatory & Quality Compliance from Purdue University.
Dr. Thomas Pillow is a Senior Scientist of the Discovery Chemistry Department at Genentech. He received his PhD from Stanford University in organic chemistry under the direction of Professor Paul Wender. Upon graduation he moved to Genentech in 2009 where he is currently a senior scientist in the discovery chemistry department leading Genentech’s effort on antibody-drug conjugates.
Songqing Na, PhD, is Research Fellow of the Immunology Research, Lilly Biotechnology Center, Eli Lilly and Co. in San Diego. Dr. Na received his PhD from Brandeis University in Boston. He was postdoctoral fellow at Harvard Medical School and then Pfizer/Yale Medical School. He joined Lilly research laboratory in Indianapolis in 1997, where he has been in research and drug discovery of Biotechnology, Inflammation, and Oncology. For the last 8 years, he has been working in immunology research and discovery in Lilly’s Biotechnology Center in San Diego. Dr. Na has published 37 peer-reviewed articles and two book chapters. Currently, Dr. Na is leading a Ph2a clinical trial team for a clinical asset.
.